R&G PharmaStudies Co. Ltd. A Cash Flow-to-Debt Ratio
R&G PharmaStudies Co. Ltd. A cash flow-to-debt ratio. R&G PharmaStudies Co. Ltd. A (301333) has a Cash Flow-to-Debt Ratio of 0.16x as of June 2022, meaning its operating cash flow of CN¥40.98 Million could theoretically repay 0% of its total liabilities (CN¥264.39 Million) in one year. Check R&G PharmaStudies Co. Ltd. A (301333) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of R&G PharmaStudies Co. Ltd. A (2019–2025)
Cash flow-to-debt ratio of R&G PharmaStudies Co. Ltd. A from 2019 to 2025. Historical debt coverage capacity for R&G PharmaStudies Co. Ltd. A across 7 annual periods. Check cash flow reinvestment rate of R&G PharmaStudies Co. Ltd. A to assess the company's total reinvestment commitment from operating cash flow.
R&G PharmaStudies Co. Ltd. A Cash Flow-to-Debt Ratio by Year (2019–2025)
R&G PharmaStudies Co. Ltd. A cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for R&G PharmaStudies Co. Ltd. A. For the full cash flow conversion analysis, see how efficiently does R&G PharmaStudies Co. Ltd. A generate cash.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.27x | CN¥114.20 Million | CN¥423.89 Million | ▼ -12.9% |
| 2024 | 0.31x | CN¥154.76 Million | CN¥500.09 Million | ▼ -48.7% |
| 2023 | 0.60x | CN¥192.56 Million | CN¥319.17 Million | ▲ +33.8% |
| 2022 | 0.45x | CN¥130.47 Million | CN¥289.35 Million | ▼ -5.7% |
| 2021 | 0.48x | CN¥114.57 Million | CN¥239.66 Million | ▲ +116.1% |
| 2020 | 0.22x | CN¥44.10 Million | CN¥199.38 Million | ▼ -57.9% |
| 2019 | 0.52x | CN¥103.48 Million | CN¥197.12 Million | — |